CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH TheracosBio has partnered with the Mark Cuban Cost Plus Drug Company to distribute Brenzavvy.
Brenzavvy (bexagliflozin), an oral sodium-glucose cotransporter 2 inhibitor, recently received approval for use as an adjunct to diet and exercise to enhance glycemic control in adult type 2 diabetes patients. This significant stride in the diabetes therapy market emanates from the TheracosBio program and is anticipated to lower treatment cost barriers, thereby expanding utilization.
Key Points:
- Brenzavvy, backed by data from 23 clinical trials involving more than 5,000 adults with type 2 diabetes, is now approved.
- The drug is administered as a 20mg tablet, once daily in the morning.
- Renal function and volume status should be assessed before initiating Brenzavvy treatment; it’s not recommended for patients with an eGFR less than 30mL/min/1.732 and contraindicated in dialysis patients.
Additional Points:
- A 30-day supply of Brenzavvy is priced at $47.85 plus shipping and handling.
Conclusion:
- The launch of Brenzavvy heralds the first phase of TheracosBio’s mission to bring cost-effective novel medications to the US population.
Endocrinology Latest Posts
- Lizzo Says These 3 Healthy Habits Helped Her Lose 60 Pounds
- Recognizing the 25 Indicators of Pancreatic Cancer
- Long-term Empagliflozin Therapy Reduces Cardiorenal Disease Progression in Patients with Chronic Kidney Disease
- Commonly Prescribed Medication for Older Adults Linked to Bone Loss, Study Finds
“The commercialization of Brenzavvy marks the first phase of the TheracosBio program to bring cost-effective novel medications to the US population, expanding markets by reducing barriers to greater utilization.”
Albert R. Collinson, PhD
President and CEO
TheracosBio
